Published in Ann Neurol on June 01, 2000
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology (2014) 1.54
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies. J Neurol Neurosurg Psychiatry (2016) 1.40
Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J (2005) 1.17
Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology (2007) 1.16
Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry (2003) 1.09
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol (2013) 1.08
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One (2010) 1.00
Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol (2008) 0.99
HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.98
Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry (2005) 0.95
Variation within DNA repair pathway genes and risk of multiple sclerosis. Am J Epidemiol (2010) 0.93
Evidence for CRHR1 in multiple sclerosis using supervised machine learning and meta-analysis in 12,566 individuals. Hum Mol Genet (2010) 0.93
Health-related quality of life assessment in people with multiple sclerosis and their family caregivers. A multicenter study in Catalonia (Southern Europe). Patient Prefer Adherence (2009) 0.93
Smoking and multiple sclerosis susceptibility. Eur J Epidemiol (2013) 0.93
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.91
Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol (2005) 0.89
Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry (2006) 0.87
Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis. J Neurol (2006) 0.85
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. Brain (2015) 0.82
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage (2013) 0.82
The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol (2011) 0.81
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. PLoS One (2015) 0.81
Isolated, relapsing and progressive demyelinating diseases of the central nervous system. J Neurol (2008) 0.80
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol (2004) 0.80
Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol (2007) 0.80
Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. J Neurol (2005) 0.80
Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. Hum Brain Mapp (2012) 0.80
Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. Eur J Neurol (2014) 0.80
Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course. J Neurol (2005) 0.79
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
White and gray matter damage in primary progressive MS: The chicken or the egg? Neurology (2015) 0.78
HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. Neurology (2014) 0.78
Application of Texture Analysis in Diagnosis of Multiple Sclerosis by Magnetic Resonance Imaging. Glob J Health Sci (2015) 0.75
CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS One (2017) 0.75
Application of the McDonald criteria in Latin America. Mult Scler J Exp Transl Clin (2017) 0.75
Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. Caspian J Intern Med (2017) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology (2007) 2.47
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol (2000) 2.10
Traumatic Rupture of the Choledochus, Associated with an Acute Hemorrhagic Pancreatitis and a Bile Peritonitis. Ann Surg (1948) 2.10
Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler (2012) 2.07
The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia (1992) 2.05
New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology (2003) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. Ned Tijdschr Geneeskd (2004) 2.03
Regional DTI differences in multiple sclerosis patients. Neuroimage (2008) 2.03